TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05788536: A Phase 1/2, Open-Label, Multicenter Trial With a Single Ascending Dose Cohort With Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tolerability, and Efficacy

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$338,640

Rescue Site Savings

+$225,760

Unlock Full NCT05788536 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05788536 Rescue Dossier →